DrugRisk Update: Bayer Estimates Yaz Settlement Total at $1.5 Billion, Includes Generics

Share Article

The DrugRisk is the web’s largest source for information on prescription drug warnings, side effects and legal news. Visit http://www.DrugRisk.com.

yaz settlement
DrugRisk has learned that Bayer has estimated the total cost to resolve Yaz lawsuits at $1.5 billion, and has set aside an additional $500 million to settle claims which are still pending or have yet to be filed.

The birth control resource center at DrugRisk.com is announcing new information for those women who have taken the contraceptives Yaz, Yasmin, Ocella or Gianvi. The maker of the drugs recently disclosed they estimate the cost of resolving injury claims at $1.5 billion.

DrugRisk.com’s mission is to improve the safety of those taking popular prescription drugs by providing the latest warnings, recalls, studies and litigation news. Patients can determine if others have experienced similar side effects and decide if they need legal advice.

The resource center has reported studies from the British Medical Journal and FDA among others, warning that birth control pills containing the hormone drospirenone, such as Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%*.

Thousands of patients have filed a Yaz lawsuit, which have been consolidated to a special federal Multi-District Litigation court in Illinois. The case is known as Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).

The latest financial reports from Bayer show the company has already spent around $1 billion to settle nearly 4,800 patient claims for blood clot injuries like deep vein thrombosis (DVT) or pulmonary embolism**.

Now, DrugRisk has learned that Bayer has estimated the total cost to resolve Yaz lawsuits at $1.5 billion, and has set aside an additional $500 million to settle claims which are still pending or have yet to be filed***.

Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz, Yasmin, Ocella or Gianvi is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options and a potential Yaz settlement.

Due to the specialized nature of federal MDL drug injury litigation, DrugRisk cautions that patients should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.

For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*British Medical Journal, October 25, 2011, University of Copenhagen; FDA, October 27, 2011, "Combined Hormonal Contraceptives and the Risk of Cardiovascular Disease Endpoints"
**Bayer 2012 Annual Report, Consolidated Financial Statement, Legal Notes, Pg 273, February 28, 2013
***newsandinsight.thomsonreuters.com/Legal/News/2013/03_-_March/Bayer_reserves_$1_5_bln_to_cover_Yasmin,_Yaz_lawsuits/

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Patient Advocate
DrugRisk
888-415-1859
Email >
Visit website